Adiponectin, diabetes and ischemic heart failure: a challenging relationship

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Syndrome

Background:

• Adiponectin (AD), an abundant adipose tissue peptide, enhances insulin sensitivity and possesses anti-inflammatory properties.
• Lower AD levels correlate with increased risk of myocardial infarction and poorer outcomes in coronary artery disease.
• Elevated AD levels paradoxically indicate a worse prognosis in heart failure (HF), with limited understanding of diabetes' influence.

Purpose of the Study:

• To investigate how type 2 diabetes mellitus modulates the relationship between adiponectin levels and ischemic heart failure.
• To determine if metabolic syndrome influences adiponectin's role in the context of heart failure.

Main Methods:

• Analysis of adiponectin levels in patients with ischemic heart failure, stratified by the presence or absence of type 2 diabetes.
• Comparison of adiponectin trends between diabetic and non-diabetic HF patients.
• Evaluation of factors like body mass index and NT-proBNP in relation to adiponectin levels.

Main Results:

• Adiponectin levels increase in advanced HF, but less significantly in diabetic patients compared to non-diabetics.
• Diabetic patients exhibited a delayed rise in AD, becoming apparent only in overt HF.
• Differences in AD behavior were not fully explained by BMI; NT-proBNP levels did not significantly differ between groups.

Conclusions:

• Adiponectin increases with chronic heart failure severity, but this effect is attenuated in type 2 diabetic patients.
• In diabetic patients with HF, the progressive rise of AD relative to left ventricular dysfunction is hampered, manifesting only in overt HF.
• Additional mechanisms likely regulate AD in patients with type 2 diabetes and coronary artery disease.